Published October 2004 in Nutritional Practitioner Magazine (ISSN 1472-0094).
Allergies and asthma are two examples of histamine-mediated allergic responses. Both conditions are increasing in frequency and are difficult to target with modern medicine. The modern approach to drug research is target specific and does not consider the natural defense mechanisms of the body or the causative factors (a cytokine TH1 to cytokine TH2 shift) underlying histamine-mediated allergic responses. Ganoderma lucidum (Reishi) as immunonutrition, with its unique array of compounds working in concert, could play a major role in treatment of histamine-mediated allergic responses.
Clinical Articles
The following section outlines the clinical papers, posters and proposals that refer to the clinical use of MRL mushroom nutrition products. This information is for healthcare practitioners only and should not be provided to members of the general public.
Download PDF
Clinical articles
-
Neuroprotective Effects of Mushroom Biomass Digestive Fractions and Gut Microbiota Metabolites in Microglial and Caenorhabditis elegans Models of Neurodegeneration
Helena Araújo-Rodrigues 1,2 , Lidia Garzón-García 3 Freni K. Tavaria 1 , Celestino Santos-Buelga 3 , Ana Sofia Salsinha 1 , João Bettencourt Relvas 2,4 , Ana M.González-Paramás 3 and Manuela E.Pintado1,* -
Characterization of Children with Intellectual Disabilities and Relevance of Mushroom Hericium Biomass Supplement to Neurocognitive Behavior
Plamen Dimitrov 1,*, Alexandra Petrova 2, Victoria Bell 3,4 and Tito Fernandes 5 -
Bioaccessibility and Bioavailability of Bioactive Compounds from Mushroom Biomass Following in vitro Gastrointestinal Digestion presented at the CIPCA 2025 X International Conference on Food Proteins and Collides June 16-18, 2025 in Porto Portugal.
Helena Araújo-Rodrigues, Manuela Machado, João B. Relvas , Freni K. Tavaria, Manuela Pintado -
Neuroprotective Effects of Mushroom Biomass: Impact of Serum-Available and Gut Microbiota Metabolites in Caenorhabditis elegans Models of Alzheimer’s Disease. Presented on June 13th at the XXIII EURO FOODCHEM 2025 Conference in Bratislava, Slovakia
Helena Araújo-Rodrigues,Lidia Garzón-García, João B. Relvas, Freni K. Tavaria, Celestino Santos-Buelga, Ana M. González-Paramás, and Manuela E. Pintado